Completion of target enrollment in the phase II EffiKIR trial

• Data on primary efficacy endpoint Leukemia-Free Survival expected end of 2015

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, today announced completion of target enrollment in the EffiKIR trial with 150 patients randomized.
EffiKIR is a double-blind placebo-controlled randomized Phase II trial of lirilumab as maintenance treatment in elderly patients with Acute Myeloid Leukemia (AML) in first complete remission.
Marcel Rozencweig, Chief Medical Officer of Innate Pharma, said: “Therapeutic approaches that prolong complete remission in elderly patients with AML are urgently needed and NK cell activation holds the promise of greatly improving survival in these patients. Target enrollment in the EffiKIR maintenance trial with lirilumab has been completed as planned and we are eagerly awaiting the results which are expected by the end of 2015”.